undamentalytics Newsletter
Sign in

Bionexus Gene Lab Corp cash flow statement

In fiscal 2025, Bionexus Gene Lab Corp's operations generated −$1.8m of cash; it spent $36,971 on capital projects, leaving free cash flow of −$1.9m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−274−2175539552−1,822−2,093−1,838−847
Depreciation and amortisation414291919183104112114
Stock-based pay————0512141795—
Capital spending−401342230149227377
Free cash flow−234−2301316552−1,972−2,320−1,875−854
Free cash flow after stock pay————552−2,483−2,461−2,670—
Shares issued742−163—————267—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BGLC vs QSIBGLC vs SEERBGLC vs YDES

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionexus Gene Lab Corp's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionexus Gene Lab Corp.